Barbara H. Ryland
Overview
Barbara H. Ryland is a senior counsel in the Washington office of Crowell & Moring's Health Care Group. Ms. Ryland brings more than 20 years of experience navigating the complex health care regulatory environment in working with health care clients in counseling, litigation and internal investigations.
Career & Education
- University of Virginia, 1983
- Duke University School of Law, 1987
- District of Columbia
- Maryland
Barbara's Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 4 min read | 04.10.26
CMS Finalizes Rate Notice for Medicare Parts C and D (CY 2027)
Client Alert | 16 min read | 12.04.25
Highlights: CMS’s Proposed Rule for Medicare Part C & D (CY 2027 NPRM)
Blog Post | 02.06.23
Representative Matters
Representative Fraud and Abuse Matters
- Counseling and review of fraud and abuse related issues for physician incentive initiative for ESRD patients.
- Drafting and review of comments on proposed rules to add value based safe harbors.
- Fraud and abuse counseling and “Best Price” impact of value based arrangements between plans and/or purchasers and pharmaceutical manufacturers.
Representative FCA Matters
- Defending Inpatient Rehabilitation Facility (IRF) against allegations of incorrect coding in order to meet CMS threshold for maintaining IRF status.
- Defending Medicare Advantage Organization (MAO) against allegations of false certification of bid information; network adequacy; and failure to meet “model of care” requirements for special needs plans.
- Defending hospital against claim for vicarious FCA liability with respect to physician who engaged in deliberately incorrect coding in order to bill for “routine” visits otherwise not covered under Medicare.
Representative Pharmacy/Pharmaceutical Related Work
- Ongoing counseling including regulatory comments on administration initiatives, including proposed amendments to Discount Safe Harbor to exclude rebates; ANPRM for the International Pricing Index (IPI) Model for Part B Drugs; and Proposed Rule for Importation of Drugs from Canada.
- Regulatory and contracting support related to 340B pricing disputes between plans, purchasers, and pharmaceutical manufacturers.
- Due diligence and licensure transfer in acquisition of national specialty pharmacy.
Barbara's Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 4 min read | 04.10.26
CMS Finalizes Rate Notice for Medicare Parts C and D (CY 2027)
Client Alert | 16 min read | 12.04.25
Highlights: CMS’s Proposed Rule for Medicare Part C & D (CY 2027 NPRM)
Blog Post | 02.06.23
Insights
Health Care - In Search of Best Practices
|01.19.16
Crowell & Moring's Regulatory Forecast 2016
Regulatory Forecast 2016: What Corporate Counsel Need to Know for the Coming Year
|01.19.16
a Crowell & Moring LLP publication
- |
09.18.15
Bloomberg BNA Pharmaceutical Law & Industry Report
- |
05.09.14
Crowell & Moring's E-Discovery Law Insights
Killing the Messenger: Is There Continuing Relevance to Messenger Model Contracting
|06.01.08
chapter in the 2008 edition of the Health Law Handbook, published by Thomson/West
Health Care Privacy in the 21st Century: Overview of the HIPAA Privacy Rule
|04.01.01
The Consultant Pharmacist
Physician Incentive Plan Rules' Implications: Throw the Stone and Watch the Ripples
|03.26.97
Analysis and Perspective, The Bureau of National Affairs' ("BNA's") Health Care Fraud Report
- |
04.07.22
Crowell & Moring’s Health Law Blog
Tennessee Proposes First of Its Kind Block Grant Program for Medicaid
|09.24.19
Crowell & Moring's Health Law Blog
Highlights from the Comments on the Proposed Elimination of Discount Safe Harbors for Rebates
|04.10.19
Crowell & Moring's Health Law Blog
MA/PDP Star Ratings: Proposed Technical Changes for 2020
|11.08.18
Crowell & Moring’s Health Law Blog
CMS Proposes Rule to Require Prescription Drug Manufacturers to Disclose Drug Prices in TV Ads
|10.18.18
Crowell & Moring’s Health Law Blog
Mount Sinai Health System to Pay $2.95 Million in 60-Day Overpayment FCA Settlement
|08.25.16
Crowell & Moring's Health Law Blog
- |
02.06.15
Crowell & Moring's Health Law Blog
Barbara's Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 4 min read | 04.10.26
CMS Finalizes Rate Notice for Medicare Parts C and D (CY 2027)
Client Alert | 16 min read | 12.04.25
Highlights: CMS’s Proposed Rule for Medicare Part C & D (CY 2027 NPRM)
Blog Post | 02.06.23




